Flagship Harbor Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.27M | Sell |
28,893
-115
| -0.4% | -$24.7K | 0.28% | 90 |
|
|
2026
Q1 | $6.31M | Sell |
29,008
-178
| -0.6% | -$39.5K | 0.28% | 88 |
|
|
2025
Q4 | $6.67M | Sell |
29,186
-4,127
| -12% | -$940K | 0.31% | 75 |
|
|
2025
Q3 | $7.71M | Buy |
33,313
+222
| +0.7% | +$45.2K | 0.34% | 67 |
|
|
2025
Q2 | $6.14M | Sell |
33,091
-11
| -0% | -$2.04K | 0.29% | 77 |
|
|
2025
Q1 | $6.94M | Buy |
33,102
+50
| +0.2% | +$9.72K | 0.36% | 61 |
|
|
2024
Q4 | $5.87M | Buy |
33,052
+173
| +0.5% | +$31.8K | 0.31% | 63 |
|
|
2024
Q3 | $6.49M | Sell |
32,879
-666
| -2% | -$124K | 0.36% | 61 |
|
|
2024
Q2 | $5.75M | Buy |
33,545
+1,318
| +4% | +$218K | 0.35% | 61 |
|
|
2024
Q1 | $5.87M | Sell |
32,227
-1,066
| -3% | -$184K | 0.38% | 58 |
|
|
2023
Q4 | $5.16M | Buy |
33,293
+1,790
| +6% | +$261K | 0.38% | 55 |
|
|
2023
Q3 | $4.7M | Sell |
31,503
-1,315
| -4% | -$193K | 0.39% | 58 |
|
|
2023
Q2 | $4.42M | Sell |
32,818
-1,369
| -4% | -$201K | 0.37% | 62 |
|
|
2023
Q1 | $5.45M | Buy |
34,187
+3,934
| +13% | +$601K | 0.51% | 44 |
|
|
2022
Q4 | $4.89M | Buy |
30,253
+503
| +2% | +$77.1K | 0.5% | 45 |
|
|
2022
Q3 | $3.99M | Sell |
29,750
-1,243
| -4% | -$178K | 0.46% | 47 |
|
|
2022
Q2 | $4.75M | Buy |
30,993
+929
| +3% | +$142K | 0.53% | 38 |
|
|
2022
Q1 | $4.87M | Buy |
30,064
+436
| +1% | +$63.3K | 0.47% | 44 |
|
|
2021
Q4 | $4.01M | Sell |
29,628
-857
| -3% | -$101K | 0.38% | 61 |
|
|
2021
Q3 | $3.43M | Hold |
30,485
| – | – | 0.37% | 64 |
|
|
2021
Q2 | $3.43M | Buy |
30,485
+410
| +1% | +$46.2K | 0.37% | 64 |
|
|
2021
Q1 | $3.25M | Buy |
30,075
+1,028
| +4% | +$110K | 0.37% | 65 |
|
|
2020
Q4 | $3.11M | Buy |
29,047
+3,194
| +12% | +$307K | 0.39% | 58 |
|
|
2020
Q3 | $2.26M | Sell |
25,853
-3,151
| -11% | -$297K | 0.31% | 67 |
|
|
2020
Q2 | $2.85M | Buy |
29,004
+3,331
| +13% | +$293K | 0.42% | 49 |
|
|
2020
Q1 | $1.96M | Buy |
25,673
+1,653
| +7% | +$141K | 0.39% | 51 |
|
|
2019
Q4 | $2.13M | Sell |
24,020
-2,160
| -8% | -$179K | 0.37% | 61 |
|
|
2019
Q3 | $1.98M | Buy |
26,180
+4,327
| +20% | +$297K | 0.39% | 57 |
|
|
2019
Q2 | $1.59M | Buy |
21,853
+276
| +1% | +$21.7K | 0.33% | 71 |
|
|
2019
Q1 | $1.74M | Buy |
21,577
+3,890
| +22% | +$318K | 0.36% | 67 |
|
|
2018
Q4 | $1.63M | Sell |
17,687
-1,463
| -8% | -$129K | 0.4% | 59 |
|
|
2018
Q3 | $1.82M | Buy |
19,150
+1,601
| +9% | +$152K | 0.34% | 68 |
|
|
2018
Q2 | $1.63M | Buy |
17,549
+2,065
| +13% | +$202K | 0.33% | 75 |
|
|
2018
Q1 | $1.41M | Buy |
15,484
+656
| +4% | +$72.1K | 0.42% | 68 |
|
|
2017
Q4 | $1.47M | Buy |
14,828
+246
| +2% | +$23.2K | 0.42% | 67 |
|
|
2017
Q3 | $1.32M | Buy |
14,582
+1,237
| +9% | +$94.2K | 0.43% | 66 |
|
|
2017
Q2 | $957K | Buy |
13,345
+547
| +4% | +$36.8K | 0.33% | 85 |
|
|
2017
Q1 | $831K | Buy |
12,798
+1,080
| +9% | +$67.9K | 0.32% | 89 |
|
|
2016
Q4 | $719K | Buy |
+11,718
| New | +$715K | 0.31% | 94 |
|
Other funds holding ABBV
Flagship Harbor Advisors's ABBV Position: Q2 2026 in Review
Flagship Harbor Advisors reduced its AbbVie (ABBV) stake by 0.4% in Q2 2026, selling an estimated $24.7K and leaving 28,893 shares worth $7.27M. The position accounts for 0.28% of the portfolio, ranked #90.
Flagship Harbor Advisors first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. The position peaked at $7.71M in Q3 2025. 2,786 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Flagship Harbor Advisors held 28,893 shares of AbbVie worth $7.27M as of Q2 2026.
- Flagship Harbor Advisors sold 115 AbbVie shares in Q2 2026, an estimated $24.7K.
- AbbVie made up 0.28% of Flagship Harbor Advisors's portfolio in Q2 2026, its #90 holding.
- Flagship Harbor Advisors first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
- Flagship Harbor Advisors's AbbVie position peaked at $7.71M in Q3 2025.
- 2,786 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.